# ICWIP (NCT02125240)

> Icotinib Versus Placebo as Adjuvant Therapy in EGFR-mutant Lung Adenocarcinoma

No report yet. It can be ordered.

- Drugs tested: icotinib
- Indication: stage II-IIIA EGFR-mutated lung adenocarcinoma

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02125240
- Phase: PHASE3
- Status: UNKNOWN
- Sponsor: Betta Pharmaceuticals Co., Ltd.
- Conditions: EGFR Positive Non-small Cell Lung Cancer; Adenocarcinoma
- Interventions: Icotinib; Placebo
- Enrollment: 124
- Primary outcome: Disease-free survival

## Indexed commentary on ICWIP so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 3 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=icwip-nct02125240